Corvus Pharmaceuticals, Inc. (CRVS) 10-Year Financial Performance & Capital Metrics

CRVS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.Show more

Revenue $0
EBITDA -$27M -18.1%
Net Income -$62M -130.5%
EPS (Diluted) -1.02 -81.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -174.85% -206.6%
ROIC -78.88% -64.0%
Debt/Equity 0.03 -3.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 80 (top 20%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 27.0% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 12.2x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM73.47%

EPS CAGR

10Y-

5Y-

3Y-

TTM42.75%

ROCE

10Y Avg-48.48%

5Y Avg-54.13%

3Y Avg-55.47%

Latest-76.32%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	148K	0	842K	847K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-148K	-594K	-842K	-847K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-3.01%	-0.42%	-0.01%	1%	-	-	-	-	-
Operating Expenses+	13.77M	36.98M	56.52M	49.22M	48.85M	43.76M	38.63M	32.56M	23.41M	27.55M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	2.42M	7.62M	10.22M	10.64M	10.88M	11.93M	9.52M	8.1M	6.88M	8.16M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	11.35M	29.36M	46.3M	38.59M	37.98M	31.83M	29.11M	24.47M	16.53M	19.39M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-13.77M	-36.98M	-56.52M	-49.22M	-48.85M	-43.76M	-38.63M	-32.56M	-23.41M	-27.55M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-77.24%	-1.69%	-0.53%	0.13%	0.01%	0.1%	0.12%	0.16%	0.28%	-0.18%
EBITDA+	-13.62M	-36.38M	-55.68M	-48.38M	-48.11M	-43.13M	-38.17M	-32.2M	-23.26M	-27.46M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-37422.08%	-1.67%	-0.53%	0.13%	0.01%	0.1%	0.11%	0.16%	0.28%	-0.18%
D&A (Non-Cash Add-back)	148K	594K	842K	847K	743K	632K	460K	367K	151K	85K
EBIT	-31.34M	-36.38M	-55.66M	-46.94M	-48.85M	-6M	-38.63M	-32.56M	-23.41M	-27.55M
Net Interest Income+	0	0	0	0	0	0	-15K	654K	1.58M	1.82M
Interest Income	35K	601K	861K	2.28M	2.18M	540K	0	654K	1.58M	1.82M
Interest Expense	0	601K	0	2.28M	2.18M	540K	15K	0	0	0
Other Income/Expense	-17.57M	601K	861K	2.28M	2.18M	37.77M	-4.61M	-8.74M	-3.62M	-34.74M
Pretax Income+	-31.34M	-36.38M	-55.66M	-46.94M	-46.67M	-6M	-43.24M	-41.31M	-27.03M	-62.29M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-35K	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-31.34M	-36.38M	-55.66M	-46.94M	-46.67M	-6M	-43.24M	-41.31M	-27.03M	-62.29M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-177.04%	-0.16%	-0.53%	0.16%	0.01%	0.87%	-6.21%	0.04%	0.35%	-1.3%
Net Income (Continuing)	-31.34M	-36.38M	-55.66M	-46.94M	-46.67M	-6M	-43.24M	-41.31M	-27.03M	-62.29M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.54	-2.36	-2.72	-1.71	-1.49	-0.20	-1.03	-0.89	-0.56	-1.02
EPS Growth %	-0.5%	-0.53%	-0.15%	0.37%	0.13%	0.87%	-4.15%	0.14%	0.37%	-0.81%
EPS (Basic)	-1.54	-2.36	-2.72	-1.71	-1.49	-0.20	-1.03	-0.89	-0.56	-1.02
Diluted Shares Outstanding	20.41M	15.42M	20.49M	27.51M	29.35M	29.48M	41.85M	46.55M	48.03M	60.99M
Basic Shares Outstanding	20.41M	15.42M	20.49M	27.51M	29.35M	29.48M	41.85M	46.55M	48.03M	60.99M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	95.66M	134.9M	90.06M	114.6M	79.34M	45.34M	71.31M	43.66M	27.96M	54.41M
Cash & Short-Term Investments	94.39M	134.9M	90.06M	114.6M	77.98M	44.26M	69.45M	42.3M	27.15M	51.96M
Cash Only	4.11M	134.9M	90.06M	114.6M	5.15M	16.45M	63.46M	13.16M	12.62M	8.74M
Short-Term Investments	90.28M	0	0	0	72.83M	27.8M	5.99M	29.14M	14.53M	43.22M
Accounts Receivable	347K	365K	132K	337K	329K	0	539K	633K	63K	216K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	722K	-1.14M	-852K	-602K	0	0	0	0	0	0
Days Inventory Outstanding	1.78K	-	-	-	-	-	-	-	-	-
Other Current Assets	208K	772K	720K	265K	486K	673K	128K	102K	220K	548K
Total Non-Current Assets+	2.8M	5.25M	4.72M	3.63M	4.3M	40.19M	38.14M	24.58M	17.6M	14.5M
Property, Plant & Equipment	1.84M	3.25M	2.67M	2.18M	3.79M	2.55M	3.64M	2.57M	1.39M	1.33M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	37.23M	34.27M	21.88M	16.12M	12.54M
Other Non-Current Assets	951K	2.01M	2.05M	1.46M	513K	414K	236K	129K	89K	632K
Total Assets+	98.46M	140.15M	94.78M	118.23M	83.65M	85.53M	109.45M	68.24M	45.55M	68.91M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	6.86%	0.42%	-0.32%	0.25%	-0.29%	0.02%	0.28%	-0.38%	-0.33%	0.51%
Total Current Liabilities+	3.07M	7.35M	9.94M	7.9M	10.22M	12.15M	9.69M	10.75M	6.87M	35.4M
Accounts Payable	1.57M	1.9M	3.45M	2M	2.45M	3.47M	1.56M	1.98M	1.52M	2.58M
Days Payables Outstanding	3.88K	-	1.5K	861	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	878K	0	0	0	0	0
Deferred Revenue (Current)	223K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	967K	3.52M	4.94M	4.38M	5.28M	180K	1.97M	1.27M	929K	30.02M
Current Ratio	31.16x	18.36x	9.06x	14.51x	7.76x	3.73x	7.36x	4.06x	4.07x	1.54x
Quick Ratio	30.93x	18.51x	9.15x	14.59x	7.76x	3.73x	7.36x	4.06x	4.07x	1.54x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	126.49M	1.41M	971K	869K	2.31M	1.23M	2.6M	1.37M	0	937K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	2.31M	1.23M	2.6M	1.37M	0	937K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	126.49M	1.41M	971K	869K	0	0	0	0	0	0
Total Liabilities	129.56M	7.35M	9.94M	7.9M	12.54M	13.38M	12.29M	12.13M	6.87M	36.34M
Total Debt+	0	0	0	0	3.19M	2.31M	3.65M	2.6M	1.37M	1.12M
Net Debt	-4.11M	-134.9M	-90.06M	-114.6M	-1.97M	-14.14M	-59.81M	-10.56M	-11.25M	-7.62M
Debt / Equity	-	-	-	-	0.04x	0.03x	0.04x	0.05x	0.04x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-61.52x	-	-21.56x	-22.39x	-81.04x	-2575.33x	-	-	-
Total Equity+	-31.1M	132.8M	84.83M	110.34M	71.11M	72.15M	97.16M	56.12M	38.68M	32.57M
Equity Growth %	-194.6%	5.27%	-0.36%	0.3%	-0.36%	0.01%	0.35%	-0.42%	-0.31%	-0.16%
Book Value per Share	-1.52	8.61	4.14	4.01	2.42	2.45	2.32	1.21	0.81	0.53
Total Shareholders' Equity	-31.1M	132.8M	84.83M	110.34M	71.11M	72.15M	97.16M	56.12M	38.68M	32.57M
Common Stock	0	2K	2K	3K	3K	3K	5K	5K	5K	7K
Retained Earnings	-31.5M	-67.87M	-123.53M	-170.47M	-217.15M	-223.14M	-266.38M	-307.69M	-334.72M	-397.01M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-45K	-39K	-41K	-34K	29K	4K	1.87M	-563K	-967K	-1.29M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-11.33M	-27.86M	-46.21M	-40.99M	-37.32M	-34.78M	-36.72M	-27.02M	-23.93M	-25.42M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-107.17%	-1.46%	-0.66%	0.11%	0.09%	0.07%	-0.06%	0.26%	0.11%	-0.06%
Net Income	-31.34M	-36.38M	-55.66M	-46.94M	-46.67M	-6M	-43.24M	-41.31M	-27.03M	-62.29M
Depreciation & Amortization	148K	594K	842K	847K	743K	632K	460K	367K	151K	85K
Stock-Based Compensation	428K	3.83M	6.23M	7.13M	7.35M	5.75M	4.23M	2.69M	2.15M	3M
Deferred Taxes	-41K	-3.83M	0	0	0	0	0	0	0	0
Other Non-Cash Items	17.64M	4.48M	-195K	-608K	-644K	-37.07M	5.07M	9.81M	4.39M	35.43M
Working Capital Changes	1.83M	3.45M	2.58M	-1.42M	1.9M	1.91M	-3.24M	1.41M	-3.59M	-1.65M
Change in Receivables	0	0	0	0	0	0	-507K	-81K	562K	-49K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	1.24M	518K	1.55M	-1.46M	450K	1.02M	-1.9M	411K	-451K	1.06M
Cash from Investing+	-92.03M	-42.56M	84.83M	-30.19M	3.25M	44.77M	21.56M	-23.28M	15.54M	-27.48M
Capital Expenditures	-1.75M	-2.2M	-266K	-355K	-25K	-76K	-5K	-269K	-34K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-90.28M	-40.36M	85.09M	-29.84M	0	44.84K	21.57K	0	0	0
Cash from Financing+	94.95M	71.36M	1.44M	65.27M	24K	1.31M	62.16M	0	7.86M	49.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-621K	4K	731K	393K	24K	88K	1.22M	0	12K	32.62M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.07M	-30.06M	-46.48M	-41.34M	-37.35M	-34.85M	-36.72M	-27.29M	-23.97M	-25.42M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-123.85%	-1.3%	-0.55%	0.11%	0.1%	0.07%	-0.05%	0.26%	0.12%	-0.06%
FCF per Share	-0.64	-1.95	-2.27	-1.50	-1.27	-1.18	-0.88	-0.59	-0.50	-0.42
FCF Conversion (FCF/Net Income)	0.36x	0.77x	0.83x	0.87x	0.80x	5.80x	0.85x	0.65x	0.89x	0.41x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-71.53%	-51.15%	-48.1%	-51.44%	-8.37%	-51.08%	-53.9%	-57.02%	-174.85%
Return on Invested Capital (ROIC)	-	-	-	-	-112.94%	-51.62%	-60.77%	-58.92%	-48.1%	-78.88%
Debt / Equity	-	-	-	-	0.04x	0.03x	0.04x	0.05x	0.04x	0.03x
Interest Coverage	-	-61.52x	-	-21.56x	-22.39x	-81.04x	-2575.33x	-	-	-
FCF Conversion	0.36x	0.77x	0.83x	0.87x	0.80x	5.80x	0.85x	0.65x	0.89x	0.41x

Frequently Asked Questions

Growth & Financials

Corvus Pharmaceuticals, Inc. (CRVS) grew revenue by 0.0% over the past year. Growth has been modest.

Corvus Pharmaceuticals, Inc. (CRVS) reported a net loss of $15.1M for fiscal year 2024.

Dividend & Returns

Corvus Pharmaceuticals, Inc. (CRVS) has a return on equity (ROE) of -174.9%. Negative ROE indicates the company is unprofitable.

Corvus Pharmaceuticals, Inc. (CRVS) had negative free cash flow of $32.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Corvus Pharmaceuticals, Inc. (CRVS) 10-Year Financial Performance & Capital Metrics

CRVS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$27M -18.1%
Net Income -$62M -130.5%
EPS (Diluted) -1.02 -81.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -174.85% -206.6%
ROIC -78.88% -64.0%
Debt/Equity 0.03 -3.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 80 (top 20%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 27.0% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 12.2x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM73.47%

EPS CAGR

10Y-

5Y-

3Y-

TTM42.75%

ROCE

10Y Avg-48.48%

5Y Avg-54.13%

3Y Avg-55.47%

Latest-76.32%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	148K	0	842K	847K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-148K	-594K	-842K	-847K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-3.01%	-0.42%	-0.01%	1%	-	-	-	-	-
Operating Expenses+	13.77M	36.98M	56.52M	49.22M	48.85M	43.76M	38.63M	32.56M	23.41M	27.55M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	2.42M	7.62M	10.22M	10.64M	10.88M	11.93M	9.52M	8.1M	6.88M	8.16M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	11.35M	29.36M	46.3M	38.59M	37.98M	31.83M	29.11M	24.47M	16.53M	19.39M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-13.77M	-36.98M	-56.52M	-49.22M	-48.85M	-43.76M	-38.63M	-32.56M	-23.41M	-27.55M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-77.24%	-1.69%	-0.53%	0.13%	0.01%	0.1%	0.12%	0.16%	0.28%	-0.18%
EBITDA+	-13.62M	-36.38M	-55.68M	-48.38M	-48.11M	-43.13M	-38.17M	-32.2M	-23.26M	-27.46M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-37422.08%	-1.67%	-0.53%	0.13%	0.01%	0.1%	0.11%	0.16%	0.28%	-0.18%
D&A (Non-Cash Add-back)	148K	594K	842K	847K	743K	632K	460K	367K	151K	85K
EBIT	-31.34M	-36.38M	-55.66M	-46.94M	-48.85M	-6M	-38.63M	-32.56M	-23.41M	-27.55M
Net Interest Income+	0	0	0	0	0	0	-15K	654K	1.58M	1.82M
Interest Income	35K	601K	861K	2.28M	2.18M	540K	0	654K	1.58M	1.82M
Interest Expense	0	601K	0	2.28M	2.18M	540K	15K	0	0	0
Other Income/Expense	-17.57M	601K	861K	2.28M	2.18M	37.77M	-4.61M	-8.74M	-3.62M	-34.74M
Pretax Income+	-31.34M	-36.38M	-55.66M	-46.94M	-46.67M	-6M	-43.24M	-41.31M	-27.03M	-62.29M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-35K	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-31.34M	-36.38M	-55.66M	-46.94M	-46.67M	-6M	-43.24M	-41.31M	-27.03M	-62.29M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-177.04%	-0.16%	-0.53%	0.16%	0.01%	0.87%	-6.21%	0.04%	0.35%	-1.3%
Net Income (Continuing)	-31.34M	-36.38M	-55.66M	-46.94M	-46.67M	-6M	-43.24M	-41.31M	-27.03M	-62.29M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.54	-2.36	-2.72	-1.71	-1.49	-0.20	-1.03	-0.89	-0.56	-1.02
EPS Growth %	-0.5%	-0.53%	-0.15%	0.37%	0.13%	0.87%	-4.15%	0.14%	0.37%	-0.81%
EPS (Basic)	-1.54	-2.36	-2.72	-1.71	-1.49	-0.20	-1.03	-0.89	-0.56	-1.02
Diluted Shares Outstanding	20.41M	15.42M	20.49M	27.51M	29.35M	29.48M	41.85M	46.55M	48.03M	60.99M
Basic Shares Outstanding	20.41M	15.42M	20.49M	27.51M	29.35M	29.48M	41.85M	46.55M	48.03M	60.99M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	95.66M	134.9M	90.06M	114.6M	79.34M	45.34M	71.31M	43.66M	27.96M	54.41M
Cash & Short-Term Investments	94.39M	134.9M	90.06M	114.6M	77.98M	44.26M	69.45M	42.3M	27.15M	51.96M
Cash Only	4.11M	134.9M	90.06M	114.6M	5.15M	16.45M	63.46M	13.16M	12.62M	8.74M
Short-Term Investments	90.28M	0	0	0	72.83M	27.8M	5.99M	29.14M	14.53M	43.22M
Accounts Receivable	347K	365K	132K	337K	329K	0	539K	633K	63K	216K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	722K	-1.14M	-852K	-602K	0	0	0	0	0	0
Days Inventory Outstanding	1.78K	-	-	-	-	-	-	-	-	-
Other Current Assets	208K	772K	720K	265K	486K	673K	128K	102K	220K	548K
Total Non-Current Assets+	2.8M	5.25M	4.72M	3.63M	4.3M	40.19M	38.14M	24.58M	17.6M	14.5M
Property, Plant & Equipment	1.84M	3.25M	2.67M	2.18M	3.79M	2.55M	3.64M	2.57M	1.39M	1.33M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	37.23M	34.27M	21.88M	16.12M	12.54M
Other Non-Current Assets	951K	2.01M	2.05M	1.46M	513K	414K	236K	129K	89K	632K
Total Assets+	98.46M	140.15M	94.78M	118.23M	83.65M	85.53M	109.45M	68.24M	45.55M	68.91M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	6.86%	0.42%	-0.32%	0.25%	-0.29%	0.02%	0.28%	-0.38%	-0.33%	0.51%
Total Current Liabilities+	3.07M	7.35M	9.94M	7.9M	10.22M	12.15M	9.69M	10.75M	6.87M	35.4M
Accounts Payable	1.57M	1.9M	3.45M	2M	2.45M	3.47M	1.56M	1.98M	1.52M	2.58M
Days Payables Outstanding	3.88K	-	1.5K	861	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	878K	0	0	0	0	0
Deferred Revenue (Current)	223K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	967K	3.52M	4.94M	4.38M	5.28M	180K	1.97M	1.27M	929K	30.02M
Current Ratio	31.16x	18.36x	9.06x	14.51x	7.76x	3.73x	7.36x	4.06x	4.07x	1.54x
Quick Ratio	30.93x	18.51x	9.15x	14.59x	7.76x	3.73x	7.36x	4.06x	4.07x	1.54x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	126.49M	1.41M	971K	869K	2.31M	1.23M	2.6M	1.37M	0	937K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	2.31M	1.23M	2.6M	1.37M	0	937K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	126.49M	1.41M	971K	869K	0	0	0	0	0	0
Total Liabilities	129.56M	7.35M	9.94M	7.9M	12.54M	13.38M	12.29M	12.13M	6.87M	36.34M
Total Debt+	0	0	0	0	3.19M	2.31M	3.65M	2.6M	1.37M	1.12M
Net Debt	-4.11M	-134.9M	-90.06M	-114.6M	-1.97M	-14.14M	-59.81M	-10.56M	-11.25M	-7.62M
Debt / Equity	-	-	-	-	0.04x	0.03x	0.04x	0.05x	0.04x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-61.52x	-	-21.56x	-22.39x	-81.04x	-2575.33x	-	-	-
Total Equity+	-31.1M	132.8M	84.83M	110.34M	71.11M	72.15M	97.16M	56.12M	38.68M	32.57M
Equity Growth %	-194.6%	5.27%	-0.36%	0.3%	-0.36%	0.01%	0.35%	-0.42%	-0.31%	-0.16%
Book Value per Share	-1.52	8.61	4.14	4.01	2.42	2.45	2.32	1.21	0.81	0.53
Total Shareholders' Equity	-31.1M	132.8M	84.83M	110.34M	71.11M	72.15M	97.16M	56.12M	38.68M	32.57M
Common Stock	0	2K	2K	3K	3K	3K	5K	5K	5K	7K
Retained Earnings	-31.5M	-67.87M	-123.53M	-170.47M	-217.15M	-223.14M	-266.38M	-307.69M	-334.72M	-397.01M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-45K	-39K	-41K	-34K	29K	4K	1.87M	-563K	-967K	-1.29M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-11.33M	-27.86M	-46.21M	-40.99M	-37.32M	-34.78M	-36.72M	-27.02M	-23.93M	-25.42M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-107.17%	-1.46%	-0.66%	0.11%	0.09%	0.07%	-0.06%	0.26%	0.11%	-0.06%
Net Income	-31.34M	-36.38M	-55.66M	-46.94M	-46.67M	-6M	-43.24M	-41.31M	-27.03M	-62.29M
Depreciation & Amortization	148K	594K	842K	847K	743K	632K	460K	367K	151K	85K
Stock-Based Compensation	428K	3.83M	6.23M	7.13M	7.35M	5.75M	4.23M	2.69M	2.15M	3M
Deferred Taxes	-41K	-3.83M	0	0	0	0	0	0	0	0
Other Non-Cash Items	17.64M	4.48M	-195K	-608K	-644K	-37.07M	5.07M	9.81M	4.39M	35.43M
Working Capital Changes	1.83M	3.45M	2.58M	-1.42M	1.9M	1.91M	-3.24M	1.41M	-3.59M	-1.65M
Change in Receivables	0	0	0	0	0	0	-507K	-81K	562K	-49K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	1.24M	518K	1.55M	-1.46M	450K	1.02M	-1.9M	411K	-451K	1.06M
Cash from Investing+	-92.03M	-42.56M	84.83M	-30.19M	3.25M	44.77M	21.56M	-23.28M	15.54M	-27.48M
Capital Expenditures	-1.75M	-2.2M	-266K	-355K	-25K	-76K	-5K	-269K	-34K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-90.28M	-40.36M	85.09M	-29.84M	0	44.84K	21.57K	0	0	0
Cash from Financing+	94.95M	71.36M	1.44M	65.27M	24K	1.31M	62.16M	0	7.86M	49.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-621K	4K	731K	393K	24K	88K	1.22M	0	12K	32.62M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.07M	-30.06M	-46.48M	-41.34M	-37.35M	-34.85M	-36.72M	-27.29M	-23.97M	-25.42M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-123.85%	-1.3%	-0.55%	0.11%	0.1%	0.07%	-0.05%	0.26%	0.12%	-0.06%
FCF per Share	-0.64	-1.95	-2.27	-1.50	-1.27	-1.18	-0.88	-0.59	-0.50	-0.42
FCF Conversion (FCF/Net Income)	0.36x	0.77x	0.83x	0.87x	0.80x	5.80x	0.85x	0.65x	0.89x	0.41x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-71.53%	-51.15%	-48.1%	-51.44%	-8.37%	-51.08%	-53.9%	-57.02%	-174.85%
Return on Invested Capital (ROIC)	-	-	-	-	-112.94%	-51.62%	-60.77%	-58.92%	-48.1%	-78.88%
Debt / Equity	-	-	-	-	0.04x	0.03x	0.04x	0.05x	0.04x	0.03x
Interest Coverage	-	-61.52x	-	-21.56x	-22.39x	-81.04x	-2575.33x	-	-	-
FCF Conversion	0.36x	0.77x	0.83x	0.87x	0.80x	5.80x	0.85x	0.65x	0.89x	0.41x

Frequently Asked Questions

Growth & Financials

Corvus Pharmaceuticals, Inc. (CRVS) grew revenue by 0.0% over the past year. Growth has been modest.

Corvus Pharmaceuticals, Inc. (CRVS) reported a net loss of $15.1M for fiscal year 2024.

Dividend & Returns

Corvus Pharmaceuticals, Inc. (CRVS) has a return on equity (ROE) of -174.9%. Negative ROE indicates the company is unprofitable.

Corvus Pharmaceuticals, Inc. (CRVS) had negative free cash flow of $32.2M in fiscal year 2024, likely due to heavy capital investments.